Welcome to our dedicated page for SANUWAVE Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SANUWAVE Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SANUWAVE Health's regulatory disclosures and financial reporting.
Form 4 filing snapshot: On 06/30/2025, SANUWAVE Health, Inc. (SNWV) reported a single insider transaction. Chief Executive Officer, Director and 10% owner Morgan C. Frank received a fully-vested stock option for 1,574 common shares at an exercise price of $32.86 per share, expiring 06/30/2030. The filing shows no open-market purchases or sales of common stock, and Mr. Frank now directly holds 1,574 derivative securities. The transaction appears to be routine executive compensation and is unlikely to meaningfully affect the company’s near-term share supply or insider sentiment.
Sanuwave Health (Nasdaq: SNWV) filed an 8-K announcing its 2025 Annual Meeting will be held on August 19, 2025. Stockholders of record at the close of business on July 8, 2025 may vote.
Because no annual meeting occurred in 2024, the company set an accelerated deadline of July 7, 2025 for (1) Rule 14a-8 stockholder proposals, (2) advance-notice director nominations or other business under the bylaws, and (3) universal-proxy notices required by Rule 14a-19. All written submissions must be delivered to the corporate secretary at the Eden Prairie, Minnesota headquarters.
SANUWAVE Health has filed a Form 144 notice indicating a proposed sale of 155,373 shares of common stock with an aggregate market value of $5,058,944.88. The securities were originally acquired on October 18, 2024, through the conversion of convertible notes and warrants into common stock.
Key transaction details:
- Broker: Vanguard Marketing Corporation (El Paso, TX)
- Trading Venue: NASDAQ
- Planned Sale Date: June 25, 2025
- Total Outstanding Shares: 8,555,616
The Form 144 indicates that the seller has no material adverse information about SANUWAVE's operations that hasn't been publicly disclosed. No other securities sales by the same person were reported in the past 3 months. This planned sale represents approximately 1.82% of the company's outstanding shares.